Business
Stuart Paynter starts as new CFO
Stuart Paynter starts as new CFO.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 0929P Oxford Biomedica PLC 29 August 2017 \n\n \n \n \n \n \n \n \n \nOxford BioMedica: Stuart Paynter starts as new Chief Financial Officer \n \n \nOxford, UK - 29 August 2017: Oxford BioMedica plc (LSE: OXB) (\"OXB\" or \"the Group\"), a leading gene and cell therapy group, confirms that, as previously announced on 28 February 2017, Stuart Paynter today joins the Group as Chief Financial Officer and member of the Board of Directors. Tim Watts, the outgoing Chief Financial Officer, will remain with the Group until Friday 29 September 2017, at which point he will step down from the Board of Directors and leave the Group.\n \n \n- Ends -\n \nFor further information, please contact:\nOxford BioMedica plc: Tel: +44 (0)1865 783 000\nJohn Dawson, Chief Executive Officer\nStuart Paynter, Chief Financial Officer\nTim Watts\n \nFinancial PR Enquiries: Tel: +44 (0)20 3709 5700\nMary-Jane Elliott / Matthew Neal / Philippa Gardner / Laura Thornton\nConsilium Strategic Communications\n \n \nAbout Oxford BioMedica\nOxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the \"Group\") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Orchard Therapeutics and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Ox...